About Co-Diagnostics (NASDAQ:CODX)
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-4.42592592592593
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-3,935.44%
Return on Assets-479.06%
Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions
What is Co-Diagnostics' stock symbol?
Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."
Who are some of Co-Diagnostics' key competitors?
Some companies that are related to Co-Diagnostics include Brainstorm Cell Therapeutics (BCLI), Navidea Biopharmaceuticals (NAVB), NovaBay Pharmaceuticals (NBY), Abzena (ABZA), CytRx (CYTR), Immutep (IMMP), Caladrius Biosciences (CLBS), Cleveland BioLabs (CBLI), OvaScience (OVAS), Can Fite Biopharma (CANF), Vernalis (VER), AEterna Zentaris (AEZS), Oncobiologics (ONS), Repros Therapeutics (RPRX), Prana Biotechnology (PRAN), ReNeuron Group (RENE), Synairgen (SNG) and Burcon NutraScience (BUR).
Who are Co-Diagnostics' key executives?
Co-Diagnostics' management team includes the folowing people:
- Dwight H. Egan, Chairman of the Board, President, Chief Executive Officer (Age 62)
- Reed L. Benson, Chief Financial Officer, Secretary (Age 70)
- Brent Satterfield, Chief Science Officer, Director (Age 40)
- Edward J. Borkowski CPA, Independent Director (Age 58)
- Frank J. Kiesner, Independent Director (Age 72)
- Richard S. Serbin, Independent Director (Age 72)
When did Co-Diagnostics IPO?
(CODX) raised $9 million in an IPO on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO.
When did the company's lock-up period expire?
Co-Diagnostics' lock-up period expired on Monday, January 8th. Co-Diagnostics had issued 1,178,532 shares in its initial public offering on July 12th. The total size of the offering was $7,071,192 based on an initial share price of $6.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
How do I buy Co-Diagnostics stock?
Shares of Co-Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Co-Diagnostics' stock price today?
One share of Co-Diagnostics stock can currently be purchased for approximately $2.24.
How big of a company is Co-Diagnostics?
Co-Diagnostics has a market capitalization of $29.36 million.
How can I contact Co-Diagnostics?
Co-Diagnostics' mailing address is 4049 S Highland Dr, SALT LAKE CITY, UT 84124-1664, United States. The company can be reached via phone at +1-801-2789769.
MarketBeat Community Rating for Co-Diagnostics (CODX)MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Co-Diagnostics (NASDAQ:CODX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Co-Diagnostics (NASDAQ:CODX)
No earnings announcements for this company have been tracked by MarketBeat.com
Co-Diagnostics (NASDAQ:CODX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Co-Diagnostics (NASDAQ:CODX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Co-Diagnostics (NASDAQ CODX)
No insider trades for this company have been tracked by MarketBeat.com
Co-Diagnostics (NASDAQ CODX) News Headlines
|Co-Diagnostics, Inc. Initiates Vector Control Program in Dominican Republic|
finance.yahoo.com - January 30 at 9:40 AM
|Co-Diagnostics Inc's Lock-Up Period Will End on January 8th (NASDAQ:CODX)|
www.americanbankingnews.com - January 1 at 1:16 AM
|Co-Diagnostics, Inc. Announces Sale of Molecular Diagnostic Tests, Including Zika Virus, to Major Caribbean Laboratory|
finance.yahoo.com - December 12 at 9:21 AM
|TJR Coatings Inc. Announces the Entering into of a Share Purchase Agreement to Acquire all of the Shares of DNA Logix Canada Inc.|
www.finanznachrichten.de - November 24 at 4:00 PM
|How Does Co-Diagnostics Inc (CODX) Compare To The Healthcare Sector?|
finance.yahoo.com - November 21 at 5:33 PM
|Co-Diagnostics, Inc. Reports Q3 Financial Results and Updates Corporate Developments|
finance.yahoo.com - November 16 at 12:59 PM
|Co-Diagnostics, Inc. Products to Be Presented at Fair of Havana 2017|
finance.yahoo.com - October 31 at 6:37 PM
|Who Owns Co-Diagnostics Inc (CODX)?|
finance.yahoo.com - October 20 at 6:51 PM
|Co-Diagnostics, Inc. to Present Zika Tests to Dominican Republic Ministry of Health|
finance.yahoo.com - October 16 at 6:10 PM
|Co-Diagnostics, Inc. to Present at NewsMakers Conference 2017|
finance.yahoo.com - September 7 at 5:28 PM
|Co-Diagnostics (CODX) to Sign Purchase Agreement with MEDCIS Pathlabs|
www.streetinsider.com - September 6 at 5:25 PM
|Co-Diagnostics, Inc. to Sign Purchase Agreement with MEDCIS Pathlabs|
finance.yahoo.com - September 5 at 6:59 PM
|Co-Diagnostics, Inc. (CODX)|
finance.yahoo.com - August 27 at 9:51 PM
|Co-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin|
finance.yahoo.com - August 24 at 5:32 PM
|Co-Diagnostics, Inc. CEO to Present at 2017 SALSS|
finance.yahoo.com - August 22 at 11:02 PM
|Co-Diagnostics Inc's (CODX) Quiet Period Set To End on August 21st|
www.americanbankingnews.com - August 14 at 1:20 AM
|Co-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit|
finance.yahoo.com - August 10 at 6:41 PM
|Co-Diagnostics, Inc. to Attend AACC 2017|
finance.yahoo.com - August 2 at 6:12 PM
|Co-Diagnostics, Inc. Announces Joint Venture in India|
finance.yahoo.com - August 1 at 12:23 PM
|Co-Diagnostics, Inc. Verifies Zika CoPrimer™ Test|
finance.yahoo.com - August 1 at 12:23 PM
|Co-Diagnostics (NASDAQ:CODX) to Raise $9 Million in IPO|
www.americanbankingnews.com - July 8 at 10:20 AM
Co-Diagnostics (NASDAQ:CODX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Co-Diagnostics (NASDAQ:CODX) Income Statement, Balance Sheet and Cash Flow Statement
Co-Diagnostics (NASDAQ CODX) Stock Chart for Thursday, February, 22, 2018